Calamos Advisors
KRYS icon

Calamos Advisors’s Krystal Biotech KRYS Stock Holding History

Calamos Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-15,705
Closed -$1.95M – 996
2023
Q4 		$1.95M Sell
15,705
-9,942
-39% -$1.1M 0.01% 607
2023
Q3 		$2.98M Buy
25,647
+5,036
+24% +$614K 0.02% 581
2023
Q2 		$2.42M Buy
20,611
+9,090
+79% +$928K 0.01% 642
2023
Q1 		$922K Buy
+11,521
New +$905K ﹤0.01% 820

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Calamos Advisors's KRYS Position: Q1 2024 in Review

Calamos Advisors sold out of Krystal Biotech (KRYS) in Q1 2024, closing a stake of 15,705 shares — an estimated $1.95M sold.

Calamos Advisors first reported a position in KRYS in Q1 2023 and held it in 4 quarters. The position peaked at $2.98M in Q3 2023. 234 funds tracked by Wall St. Rank hold KRYS as of Q1 2024.

  • Calamos Advisors reported no remaining Krystal Biotech position as of Q1 2024 after selling out during the quarter.
  • Calamos Advisors sold 15,705 Krystal Biotech shares in Q1 2024, an estimated $1.95M.
  • Calamos Advisors first reported a position in Krystal Biotech in Q1 2023 and held it in 4 quarters.
  • Calamos Advisors's Krystal Biotech position peaked at $2.98M in Q3 2023.
  • 234 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2024.

Based on Calamos Advisors's 13F filing for Q1 2024, filed 8 May 2024.